In previous bulletins, we have discussed how the psychedelic drug development landscape is becoming increasingly crowded across all major delineations (primarily molecule / indication). In February we looked at DMT, which we covered more deeply in a July edition. On the indication side, we touched on alcohol use disorder in a late-April dispatch. Out of fear of stating the obvious…
